$201 Million is the total value of Opaleye Management Inc.'s 44 reported holdings in Q1 2017. The portfolio turnover from Q4 2016 to Q1 2017 was 56.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CARA | Sell | CARA THERAPEUTICS | $7,080,000 | +60.4% | 385,000 | -18.9% | 3.52% | +35.5% |
| GNMX | Sell | AEVI GENOMIC MEDICINE INC | $1,990,000 | -74.4% | 1,070,000 | -28.7% | 0.99% | -78.4% |
| LBIO | Sell | LION BIOTECHNOLOGIES INC | $1,713,000 | -17.8% | 230,000 | -23.3% | 0.85% | -30.6% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $1,440,000 | -53.8% | 360,000 | -11.1% | 0.72% | -61.0% |
| AQXP | Sell | AQUINOX PHARMACEUTICALS INC | $1,418,000 | -72.3% | 85,000 | -72.6% | 0.71% | -76.6% |
| ABEO | Sell | ABEONA THERAPEUTICS INC | $1,375,000 | -29.1% | 275,000 | -31.2% | 0.68% | -40.2% |
| CORI | Sell | CORIUM INTERNATIONAL INC | $677,000 | -56.1% | 162,000 | -57.4% | 0.34% | -62.9% |
| AGRX | Exit | AGILE THERAPEUTICS INC | $0 | – | -15,000 | -100.0% | -0.05% | – |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -110,000 | -100.0% | -0.37% | – | |
| AKAOQ | Exit | ACHAOGEN INC | $0 | – | -80,000 | -100.0% | -0.61% | – |
| WGBS | Exit | WAFERGEN BIO-SYSTEMS INC | $0 | – | -320,000 | -100.0% | -0.93% | – |
| PTI | Exit | PROTEOSTASIS THERAPEUTICS INC | $0 | – | -150,000 | -100.0% | -1.08% | – |
| CLSD | Exit | CLEARSIDE BIOMEDICAL INC | $0 | – | -270,000 | -100.0% | -1.42% | – |
| OMER | Exit | OMEROS CORP | $0 | – | -265,300 | -100.0% | -1.55% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -170,000 | -100.0% | -2.05% | – |
| ARIA | Exit | ARIAD PHARMACEUTICALS INC | $0 | – | -1,000,000 | -100.0% | -7.33% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-31 |
| 13F-HR/A | 2024-05-29 |
| 4 | 2024-05-23 |
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.